Introduction {#sec1-1}
============

In practice of medicine, differences in response and toxicity of drugs have been reported and explored many times (Bandres et al., 2007). Interindividual differences in drug metabolism are caused by different mechanisms (Bandres et al., 2007). Finding specific metabolic pathways leading to severe toxicity could have a major role in the safe and selective treatment of cancer patients.

Irinotecan is used, either alone or in combination with 5-FU and folinic acid, for the treatment of metastatic colorectal cancer. The use of Irinotecan might be complicated with unpredictable severe toxicity (Evans and McLeod, 2003). In the past, many patients with Gilbert's syndrome showed severe toxicity of Irinotecan such as high-grade diarrhea and neutropenia, suggesting a genetic basis for the reaction (Salonga et al., 2000). In fact, inter-individual differences in drug metabolism are an important cause of adverse drug reaction or lack of drug response (Sim et al., 2013; Tracy et al., 2016). Irinotecan active metabolite (SN-38) is primarily inactivated in the liver by the bilirubin metabolizing enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1). There are reports of polymorphism of UGT1A1 (), which results in severe toxicity in rapidly dividing cells, leading to myelosuppression and delayed type diarrhea (Ratain et al., 2002; Bandres et al., 2007).

We prospectively genotyped 50 Iranian Irinotecan treated patients, to find the correlation between UGT1A1-genotype and clinical toxicity of irinotecan. Secondary end points were analyzing patients' survival and response rate based on polymorphism of the enzyme.

Material and Methods {#sec1-2}
====================

From March 2011 to December 2013, fifty patients with metastatic colorectal cancer who were treated primarily with the study protocol were registered for the present study at the Medical Oncology Department of Iran Cancer Institute. The study was approved by the ethics committee of Tehran University of Medical Sciences (TUMS). Before beginning the chemotherapy, 2 ml whole EDTA blood was taken from patients and shipped to Central Lab (Parto- Lab) within a maximum of two hours, keeping the sample at 4 °C. QIA amp DNA Blood Mini-kit was used to extract DNA from samples and Nano-Drop instrument was utilized for quality control of the extracted DNA. Genotyping was performed by PCR and DNA sequencing mentioned precisely in following references (Innocenti et al., 2004; Marsh and Hoskins, 2010; Suzuki et al., 2012).

Inclusion criteria required signed informed consent, pathology report of colorectal adenocarcinoma, measurable metastatic disease based on RESIST 1.1 criteria, normal liver, heart, kidney and hematologic laboratory parameters, and good performance status (0-2 WHO scores). Previous chemotherapy in the adjuvant setting was allowed.

Exclusion criteria included having a plan of surgery as metastasectomy, baseline bilirubin more than 2mg/dl, liver enzymes more than 3 times the upper limit of the normal range, age 75 or more and inability to do personal care (poor performance status). None of the patients had taken chemotherapy in the metastatic setting before.

Technical consideration of genotyping {#sec2-1}
-------------------------------------

Irinotecan metabolizing risk categories groups were defined as low-risk: common alleleUGT1A1: (1\*1\*), moderate risk: heterozygote for polymorphism UGT1A1: (1\*28\*) and high risk: homozygote for polymorphism UGT1A1: (28\*28\*).

Planned chemotherapy protocol (FOLFIRI) was identified as Irinotecan (Pfizer) 180mg/m2 day1, Leucovorin 400mg/m2 and 5FU 400mg/m2 bolus day 1, then 5FU 2400mg/m2 Iv 46h. The protocol was repeated every two weeks, for 12 cycles.

The researchers of the present study used NCI v3 drug reaction and QLQ-C30questionnaires to check toxicity and patients' quality of life retrospectively. A few years ago, QLQ-C30questionnaire was translated into Farsi and validated for Iranian clinical trials (Montazeri et al., 1999).

The standard moderate dose of Irinotecan was used in the present study. However, the procedure followed by decreasing 20% of Irinotecan and 5-FU dose in the subsequent cycle based on the observation of grade III or IV drug adverse reactions. Investigators received genomic test result after the second cycle of chemotherapy. Therefore, the test result had no role on the first dose modifications of Irinotecan. All of the patients received prophylactic G-CSF (Neupogen Roche) support.

In the case of late diarrhea, oral Loperamide and Ciprofloxacin were administered. Patients with febrile neutropenia were hospitalized with IV fluid and antibiotics therapy.

We used SPSS v 19 for analyses of data. Odds ratios (OR) were calculated with logistic regression. Hazard ratios (HR) were analyzed using Cox regression.

Results {#sec1-3}
=======

A total of 50 patients were registered in the present study and all of them followed to death or end of 2015. The median age of the patients was 52 years (+/-12.4). Most of the patients (70%) had more than one metastases site in peritoneum, liver, and/or lung and 13 had permanent colostomies. [Table 1](#T1){ref-type="table"} shows demographic characteristics of the patients.

###### 

Demographic Characteristics of the Patients

  Characteristic                      FOLFIRI[\*](#t1f1){ref-type="table-fn"} (n=50)   
  ----------------------------------- ------------------------------------------------ ---------
  Age (years)                                                                          
   Mean (s.d.)                        52.2                                             (12.4)
   Median (range)                     53                                               \(51\)
  WHO P.S., n (%)                                                                      
  First cycle                         6                                                (12.2)
   0                                  17                                               (34.7)
   1                                  23                                               (46.9)
   2                                  3                                                (6.1)
   3                                                                                   
  Second cycle                                                                         
   0                                  2                                                (4.1)
   1                                  14                                               (28.6)
   2                                  17                                               (34.7)
   3                                  16                                               (32.6)
  Colestomy, n (%)                                                                     
   Yes/No                             13/37                                            (26/74)
  Location of Metastasis, n (%)                                                        
   Liver                              7                                                \(14\)
   Lymph node                         21                                               \(42\)
   Lung                               4                                                \(8\)
   Perit                              6                                                \(12\)
   Other                              12                                               \(24\)
  No. of organs involved, n (%)                                                        
   1                                  14                                               (29.8)
   2                                  22                                               (46.8)
   3+                                 11                                               (23.4)
   Haemoglobin, mean (range)          11.7                                             (8.7)
   Low haemoglobin, n (%) (\<12)      24                                               \(48\)
  P-bilirubin, mean (range)                                                            
   First cycle                        2                                                \(11\)
   Second cycle                       1.1                                              (9.6)
   Overall Survival, median (range)   29                                               \(17\)

FOLFIRI, Combination chemotherapy included; 5-FU, Leucovorin, Irinotecan

The median of overall survival was 21 months (14-27). Toxicity was most frequently associated with leukopenia and diarrhea followed by infection, anemia, and fatigue. Only 2 patients showed no drug reaction. There were 25 early discontinuations of chemotherapy protocol. 9 cases were associated with severe chemotherapy toxicity and 16 with progressing disease. [Table 2](#T2){ref-type="table"} shows drug toxicity based on NCI criteria.

###### 

Relationship between Genotype of Irinotecan and Clinical Toxicity of FOLFIRI Chemotherapy

  Outcome         All   Toxicity   (%)      No toxicity    (%)     OR    (95% CI)      P-value (exact)
  --------------- ----- ---------- -------- ------------- -------- ----- ------------- -----------------
  Genotype                                                                             
   Normal         31    26         (83.9)   5             (16.1)   1                   (0.004)
   Heterozygote   13    9          (69.2)   4             (30.8)   2.3   (0.5-10.5)    
   Homozygote     6     1          (16.7)   4             (30.8)   26    (2.5-272.8)   

[Table 3](#T3){ref-type="table"} presents drug genotyping results. Thirty-one patients had UGT1A1\*1, thirteen were heterozygous, and 6 were homozygous for UGT1A1\*28/\*28. A clinically relevant increase in early toxicity was observed in patients carrying the UGT1A1\*28/\*28 genotype with an OR of 2.6(95%CI 2.5-272.8). Similarly, there was a trend of lower overall survival in homozygote group with an HR of 2.76. A statistically significant relationship was not found between the genotype and response to therapy.

###### 

Patients Performance Status Changes after Chemotherapy

  Genotype      All   Normal (%)   Heterozygote (%)   Homozygote (%)   Kendall's Tau   P-value (exact)
  ------------- ----- ------------ ------------------ ---------------- --------------- -----------------
  WHO P.S                                                                              
  1^st^ Cycle                                                                          
   0            6     4 (66.7)     2 (33.3)           0 (0)            -0.0227         (0.785)
   1            17    10 (58.8)    3 (17.6)           4 (23.5)                         
   2            23    14 (60.9)    7 (30.4)           2 (8.7)                          
   3            3     2 (66.7)     1 (33.3)           0 (0)                            
  2^nd^ Cycle                                                                          
   0            2     2 (100)      0 (0)              0 (0)            0.1666          (0.946)
   1            14    9 (64.3)     4 (23.5)           1 (7.1)                          
   2            17    11 (64.7)    4 (31.2)           2 (11.8)                         
   3            16    8 (50)       5 (26.5)           3 (18.7)                         

Although the sample size was limited, UGT1A1 28\*/28\* showed 2.7 times more association with the life-threatening toxicity of Irinotecan compared to normal variant. On the other hand, there was no significant difference between normal genotype and heterozygote state in relation to toxicity or survival ([Figure 1](#F1){ref-type="fig"}).

![Effect of Irinotecan Pharmacogenomics on Survival of the Patients in Months](APJCP-18-2803-g001){#F1}

EORTC QLQ-C30 questionnaire results would be reported in another paper.

Discussion {#sec1-4}
==========

In the present study, the relationship between Irinotecan efficacy and toxicity and pharmacogenomic of the drug metabolizing enzyme UGT1A1 was evaluated. It is obvious that there are individual differences with regard to toxicity and response to the anti-cancer drugs irrespective of age, sex, body surface area, drug interactions, and tumor stage or organ functions. In fact, disease response may be related to interindividual differences in surface proteins or enzymes interaction in drug metabolism. In this sense, one of the aspects of the personalized medicine is considering pharmacogenomic of drugs (Swen et al., 2011).

Although there are reports of fatal toxicity of Irinotecan based on high doses (more than 250mg/m2) (Hoskins et al., 2007; Swen et al., 2011), the finding of the present study revealed significant toxicity in colorectal cancer patients treated with moderate doses(180mg/m2) of Irinotecan. Unpredictable severe toxicity of Irinotecan is also addressed in other studies (Hoskins et al., 2007; Tsunedomi et al., 2014). There are reports on risk of severe toxicity in patients treated with medium doses of irinotecan in relation to homozygosity for UGT1A1\*28. For example, in the randomized controlled phase III trial Nordic VI, which, compared the effects of irinotecan either with bolus 5-FU or bolus/infused 5-FU, the prescribed dose of irinotecan was 180/m2 (Glimelius et al., 2011). They found 46% grade III or IV toxicity excluding alopecia. The most common toxicities were diarrhea and neutropenia. Nordic investigators found an increased risk of early Irinotecan-induced toxicity in patients homozygous for the UGT1A1\*28 variant (Glimelius et al., 2011).

Only 12% of our cases showed homozygote state, but 2 of our patients died because of unpredictable severe early toxicity of chemotherapy. It could be a big challenge; on one hand, in 2005, FDA approved the inclusion of UGT1A1 genotype-associated risk of toxicity on the Irinotecan package insert (<http://www.fda.gov/medwatch/SAFETY2005>); on the other hand, there are concerns about globally checking DNA sequences of UGT1A1 genes due to cost and time consumption of the test, limited available cites for detection of common UGT1A1 alleles and last but not the least, problems related to quality control of the test (emedicine.medscape.com/article/1790367-overview).

The present study indicated no statistical differences in toxicity between normal and heterozygote state of UGT1A1 genotype in metabolizing medium dose of Irinotecan in FOLFIRI regimen. Another study reported 50% and 12.5% grade III or IV toxicity in homozygote and heterozygote group of patients based on UGT1A1 genotyping with in response to using single agent Irinotecan in 350mg/m2dose(Tucano, Sugiyama,2017).

The present study has many limitations. Firstly, the sample size of the research was too small. Secondly, because of technical and financial problems in checking mutations of Dihydroprimidine -dehydrogenase (DHPD) and Thymidylate Synthase(TS) by PCR test, the probable role of polymorphism of 5-FU metabolism on severe toxicity of chemotherapy protocol cannot be ignored (Lecomte et al., 2004; Keiser, 2008; Amstutz et al., 2009; Loganayagam et al., 2010).

Thirdly, in this study only UGT1A1 genotype was checked, but not other glucuronosylation enzymes included in metabolism of Irinotecan addressed which were addressed in other studies (Glimelius et al., 2011; Swen et al., 2011). Therefore, this investigation should be considered as an exploratory research work.

Fourthly, Investigators used G-CSF generously after any cycle of chemotherapy to prevent febrile neutropenia. It causes low number of neutropenia between cycles of chemotherapy. However, two patients with a severe metabolic defect of Irinotecan died of diarrhea and sepsis that shows the importance and deadly problem of patients with homozygote state who are receiving a standard dose of the drug. They probably need lower doses of the drug from the start of treatment.

In conclusion, every oncologist likes to safe gourd his or her patients to receive the best response without obtaining too much toxicity. Genotyping of main metabolizing enzymes of Irinotecan is an action to avoid of unpredictable and life-threatening toxicity confronting homozygote patient, while others can receive the higher doses of drug safely.

It is important to pay attention to the baseline bilirubin level in serum of the patient, and family history of Gilbert disease. Patients with baseline serum total bilirubin levels of 1.0 mg/dL or more have a greater likelihood of first-cycle grade 3 or 4 toxicity than those with less bilirubin level. Patients with deficient glucuronosylation of bilirubin, such as those with Gilbert's syndrome, may be at a greater risk of myelosuppression when receiving therapy with Irinotecan Hydrochloride. It should be noted that the problem is very important and even life threatening in case of using medium to high doses of Irinotecan (180-350mg/m^2^).
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